Some innovations fail not because the science is weak, but because the strategy is.

I’m working with a biotech company that has built a successful business since 1970 by collecting bi-products from slaughterhouses in Latin America, long before the circular- or bioeconomy became part of mainstream vocabulary. For decades, they have created value from waste, supplying the pharmaceutical, agriculture, and functional food markets successfully.

Now they face a new opportunity: heme iron and hemoglobin derived from bovine blood, a highly bioavailable ingredient that can help prevent iron deficiency anemia, the world’s most widespread nutritional disorder, affecting more than two billion people.

According to the WHO and global health alliances, low- and middle-income countries face an annual economic burden exceeding $300 billion due to anemia, with productivity losses estimated at more than 4% of GDP, hampering human capital development.

The science is compelling. It points toward solving a structural global health challenge through functional foods. The purpose is undeniable. The instinct is to move fast. That is where many companies go wrong.

Don’t extinguish the fire. Direct it.

The energy behind breakthrough innovation is not the enemy, it is the engine. But fire, left unchecked, burns through capital, credibility, and timing.

Run, but know where you’re running. Use the momentum to sharpen the thinking before you accelerate execution. Speed is an advantage. Blind speed is a liability.

A product like this does not simply “enter the market.” It must navigate regulatory pathways, application formats, pricing logic, capital requirements, cultural perception, and supply chain integration.

Is it a supplement? A fortified food ingredient? An infant nutrition solution?

Each path leads to a different commercial reality. Acting without answering those questions is not agility. It is exposure. Entrepreneurial companies are often biased toward action: “Let’s start and adjust.” That mindset works in familiar markets. It rarely works in new, regulated, perception-sensitive categories.

A structured go-to-market strategy is not bureaucracy. It is alignment, between internal capabilities and external readiness.

The real question is not whether the product works; It is whether the market is ready, and for what exactly. Innovation creates value. Strategy determines whether that value is adopted. And the difference decides success or failure.